Objective: The purpose of this study was to investigate the relationship between disruption of MRI-measured resting-state functional connectivity (rs-fcMRI) brain networks and CSF levels of potentially pathogenic proteins that reflect brain pathology in Parkinson disease (PD).
Pathologic accumulation of a-synuclein contributes to nigrostriatal dopamine loss and the subsequent motor and nonmotor manifestations in Parkinson disease (PD). However, most PD studies focus on the nigrostriatal dopamine system despite evidence that pathologic a-synuclein and b-amyloid (Ab) deposition extends to cortical areas. 1 Interrogation of cortical and subcortical brain networks through MRI measures of resting-state functional connectivity (rs-fcMRI) reveals disruption of not only corticostriatal motor, but also default mode (DMN) and dorsal attention networks (DAN) in PD. [2] [3] [4] [5] [6] [7] [8] [9] [10] In Alzheimer disease (AD) biomarker studies, DMN topography and strength correspond with cortical Ab deposition. 11, 12 Furthermore, CSF Ab 42 correlates with in vivo measures of Ab deposition 13 and with DMN functional connectivity. 14, 15 Although a-synuclein neuroimaging markers are not yet available, CSF a-synuclein levels are lower in PD 16, 17 and may reflect synuclein brain pathology. Thus, determining the relationship between CSF levels of potentially pathogenic proteins and resting-state networks (RSNs) could link brain pathology and cortical dysfunction, providing key insights into the relationship between synucleinopathy and brain dysfunction in PD.
Therefore, in the present study, we investigated the relationships between functional connectivity and CSF a-synuclein, Ab 42 , and tau in PD. We hypothesized that CSF a-synuclein correlates with motor-related RSNs and that CSF Ab 42 and Ab PET (Pittsburgh compound B [PiB]) binding correlate with DMN functional connectivity. To test these hypotheses, participants with PD and controls had rs-fcMRI, PiB-PET scans, and lumbar punctures to measure CSF proteins while off PD medications. Functional connectivity analyses, including rigorous quality control for movement, 18, 19 focused on 5 major RSNs 20, 21 and striatal connectivity. 22 METHODS Standard protocol approvals, registrations, and participant consents. The Washington University in St.
Louis Human Research Protection Office and Radioactive Drug
Research Committee approved this study and participants provided written informed consent.
Participants. Participants with PD (n 5 68) were recruited through the Washington University in St. Louis Movement Disorders Center and the community between January 2006 and December 2013. Age-matched controls (n 5 27) were recruited through the participants with PD (e.g., spouses/ partners, friends). Clinical diagnosis of idiopathic PD was based on modified United Kingdom PD Society Brain Bank clinical diagnostic criteria with clear motor response to levodopa. 23 Exclusion criteria included head injury with loss of consciousness .5 minutes, neurologic diagnosis other than PD, severe psychiatric disorders (e.g., schizophrenia), treatment with dopaminergic blocking or depleting drug, or inability to complete MRI. Based on evidence of altered rs-fcMRI with mood disorders, 24 participants who reported high levels of current depression symptoms on the 15-item Geriatric Depression Scale (scores $6) 25 were excluded (7 PD, 3 control). Controls had a normal neurologic examination and no family history of PD.
Dementia evaluation. Participants completed the Clinical
Dementia Rating (CDR) 26 and Mini-Mental State Examination (MMSE) with experienced raters. PD participants with CDR $1 or MMSE ,24 were considered to have cognitive decline with functional impairment, meeting criteria for PD dementia 27 and were excluded (n 5 4). PD participants with CDR of 0.5 have cognitive impairment insufficient to meet dementia criteria 27 and were included. All controls had normal cognition (CDR 5 0 and MMSE $24).
Motor assessments. Movement disorder specialists rated motor severity using the Unified Parkinson's Disease Rating Scale motor evaluation (UPDRS-III 28 ) in the practically defined "off" state, after overnight withdrawal of PD medications. See appendix e-1 on the Neurology ® Web site at Neurology.org for motor subtype classification and calculations.
CSF protein measures. Participants completed lumbar punctures within 1 year of rs-fcMRI scans. CSF was collected and processed as described. 16 CSF a-synuclein, Ab 42 , and tau were measured using standard, commercially available ELISA kits. 16 The CSF data represent a subset of published data, 16 including only participants with rs-fcMRI.
PiB-PET imaging. Participants completed [ 11 C]-PiB-PET imaging as described. 29, 30 PiB binding potentials (BP) were calculated from the tracer distribution volume (DV) as BP 5 DV 2 1. Mean cortical BP (MCBP) (average of prefrontal cortex, gyrus rectus, lateral temporal cortex, and precuneus) were calculated for each participant; higher scores indicate more cortical fibrillar Ab. MCBP $0.18 is considered abnormally elevated. 31 To ensure controls did not have preclinical AD, 32 controls with elevated PiB (n 5 1) were excluded. Portions of these PET data have been reported. 29, 30 Resting-state fMRI. Neuroimaging was performed using a 3T Siemens Trio scanner (Erlangen, Germany) with a standard 12-channel head coil. Participants with PD were imaged after overnight withdrawal of PD medications. Structural scans included the following: T1-weighted magnetizationprepared rapid gradient echo MRI scan (repetition time [TR] 5 2,400 milliseconds [ms], inversion time 5 1,000 ms, echo time [TE] 5 16 ms, flip angle 5 8°, 0.9 mm 3 voxels) and T2-weighted MRI scan (TE 5 455 ms, TR 5 3,200 ms, 1 mm 3 voxels). Participants completed up to 3 rs-fcMRI runs (200 volumes/run, TE 5 27 ms, TR 5 2,200 ms, field of view 5 256 mm, flip angle 5 90°, 4 mm 3 voxels), with eyes closed but awake. To control for movement confounds, participants were observed throughout scan acquisitions; rs-fcMRI runs with observable sustained tremor, dyskinesia, or dystonia were excluded.
Resting-state fcMRI data were processed as previously described. 7 Preprocessing included compensation for systematic, slice-dependent time shifts, elimination of systematic odd-even slice intensity differences due to interleaved acquisition, rigid-body correction for head motion, and normalization of signal intensity (all voxels in all volumes of each run) to obtain a mode value of 1,000. fMRI scans were registered to an atlas-representative template representing equal numbers of PD and control participants to minimize registration bias. 7, 33 Additional preprocessing before seed-based correlation mapping included spatial smoothing (6 mm full width at half maximum in each direction) and temporal low-pass filtering retaining frequencies ,0.1 Hz. Signals treated as nuisance regressors included (1) 6 rigid body parameters derived from head motion correction, (2) signals extracted from regions of interest (ROIs) in white matter and CSF, and (3) the mean over the whole brain.
MRI quality assurance measures. Rigorous quality assurance (QA) measures were applied to minimize the impact of motion artifacts and movement confounds. 18, 19 fMRI runs in which head motion exceeded 0.6 mm root mean square or the voxel-wise temporal SD averaged over the brain (after full preprocessing) exceeded 0.5% were excluded. Volumes with large changes in signal intensity (DVARS .0.5% 19 ) were excluded. Participants with more than 15% volumes removed were excluded. Only participants with at least 2 usable rs-fcMRI runs, as determined by QA measures, were included. One control and 14 participants with PD were excluded on the basis of these QA measures. In the retained data, QA measures were equivalent between PD and control groups.
Network-level functional connectivity. Network-level functional connectivity analyses focused on 5 previously defined RSNs (DMN, dorsal attention [DAN], control, salience, and sensorimotor [SMN]). 20, 21 ROIs (table e-1) were defined as 5-mmradius spheres centered on Talairach atlas coordinates. 21 The time series for each ROI was extracted and correlated with all other brain voxels. Individual correlation maps for each seed were converted to Fisher z-transformed correlation maps and then averaged across groups. Functional connectivity between ROI pairs was evaluated as the mean Fisher z-transformed correlation value over expanded seed regions surrounding the second member of each pair. 21 Expanded seed regions were defined as voxels satisfying jzj . 3 in Fisher z-transformed correlation maps averaged over the entire cohort (figure 1). Composite scores representing within-RSN functional connectivity were computed as the average over diagonal blocks of ROI pairs, 21 as illustrated in figure 2B .
Striatal functional connectivity. Striatal functional connectivity was compared between groups using previously defined seeds in dorsal caudate and anterior and posterior putamen. 22 For striatal seeds (figure 1B), the group averaged Fisher z(r) maps were compared using random-effects analysis. Significant clusters, based on extent and z-score thresholds, were determined by bootstrapped Monte Carlo simulations (10,000 iterations) at a p 5 0.05 significance level to control for multiple comparisons across all brain voxels. 7 Fisher z(r) correlation coefficients for significant clusters (seed-cluster pairs) were extracted for additional correlation analyses with CSF and disease-severity measures.
Statistical analyses. First, group differences in RSN composite scores and CSF protein levels were established with one-way analyses of variance. To test the primary hypothesis of correlations between CSF protein levels and functional connectivity in PD, Pearson partial correlations, controlling for the potential effects of age on protein levels and functional connectivity, were computed separately for each group. Correlation analyses also tested associations among disease severity, RSN composite scores, and CSF protein levels. Nonparametric Spearman correlations were used for the UPDRS-III rank-order motor ratings. Data were analyzed with PASW version 22 (IBM, Chicago, IL). Extreme values (.3 SD) were excluded as statistical outliers. All tests were 2-tailed and p # 0.05 was considered statistically significant.
RESULTS Participants. Forty-three PD participants without dementia and 22 controls had usable rs-fcMRI data after applying QA measures (see table 1 ). For these participants, QA measures did not differ across groups (p . 0.25). PD and control groups had similar ages (p 5 0.55), but the PD group was slightly more educated (F 1,63 5 6.68, p 5 0.01) and had more men (x 2 5 4.09, degrees of freedom [df] 5 1, p 5 0.04). Therefore, education and sex were included as covariates for between-group analyses.
RSN functional connectivity differences. Topographically, PD and control groups displayed the typical RSN connectivity patterns ( figure 2A) . However, the PD group exhibited reduced functional connectivity within the SMN (analysis of covariance [ANCO-VA], education and sex as covariates; F 1,61 5 6.20, p 5 0.02; figure 2 , B and C) and stronger DMN functional connectivity after excluding one control outlier (ANCOVA; F 1,60 5 4.12, p 5 0.05; figure 2 , B and C). Composite RSN scores did not differ between groups for DAN (ANCOVA; p 5 0.57), control network (ANCOVA; p 5 0.26), or salience network (ANCOVA; p 5 0.25) (figures 2B and e-1). Additional internetwork connectivity comparisons are presented in appendix e-1.
Striatal functional connectivity. Based on striatal seeds, dorsal caudate functional connectivity differed between groups, with significant clusters in cerebellum and temporal-parietal junction ( figure 3 ). For control participants, the left dorsal caudate positively correlated with the cerebellum and negatively correlated with the temporal-parietal junction; in contrast, the PD group exhibited a relative lack of any correlation between left dorsal caudate and these regions. None of the other striatal seeds yielded significant group differences.
CSF protein level differences. Participants with PD had lower CSF a-synuclein (ANCOVA; F 1,61 5 5.05, p 5 0.03) and Ab 42 (ANCOVA; F 1,61 5 4.35, p 5 0.04) than controls, but CSF tau did not differ between groups (ANCOVA; p 5 0.95) even after excluding outliers (ANCOVA; p 5 0.95) (figure e-2).
CSF proteins and functional connectivity in PD. Partial correlations, controlling for age, tested the relationship PiB and functional connectivity. PiB MCBP did not correlate with the DMN for PD or control groups (p . 0.48). Only 7 (16.3%) participants with PD had abnormally elevated PiB binding (PiB 1 ).
Correlations with disease severity. We also investigated the correlation between motor severity, as determined by duration of PD, UPDRS-III OFF total and motor subscale scores, and RSNs or CSF protein levels. The motor subscale analyses are provided in appendix e-1. UPDRS-III ratings did not correlate with any RSN (p . 0.16), including the SMN (r 5 20.26, df 5 41, p 5 0.10), or seed-cluster pairs (p . 0.11). Similarly, CSF protein levels did not correlate with motor severity measures (p . 0.11).
DISCUSSION Disruption of SMN functional connectivity in PD correlated with reduced CSF levels of a-synuclein. Participants with PD with the lowest CSF a-synuclein levels had the greatest reduction in SMN functional connectivity. This relationship was unique to the PD group and was not found for the control group. In contrast, DMN functional connectivity did not correlate with either CSF Ab 42 or PiB binding in PD; instead, CSF Ab 42 correlated with DMN functional connectivity only in the control group. These results suggest that abnormal a-synuclein accumulation contributes to disruption of particular RSNs in PD. The relationship between CSF a-synuclein and functional connectivity provides new evidence for the functional significance of a-synuclein in the pathophysiology of PD. Since CSF levels of a-synuclein likely reflect abnormal brain deposition of a-synuclein, the correlation between CSF levels and SMN coherence indicates that a-synuclein may directly disrupt cortical function. Disruption of striatal functional connectivity for the dorsal caudate did not correlate with CSF protein levels. Given that direct dopaminergic denervation occurs mostly in striatum and CSF levels correlate with other resting-state cortical networks, these findings may indicate that the effects of a-synuclein extend beyond nigrostriatal dopaminergic denervation. This also offers a possible explanation for reports of disrupted motor network functional connectivity in PD while on medication. 7 Of note, DAN functional connectivity negatively correlated with CSF a-synuclein, which may reflect increased reliance on external information frequently observed in PD 34 since DAN activity is associated with externally directed cognition. 35 This finding suggests that even in PD without dementia, changes in a-synuclein metabolism influence nonmotor cortical functional connectivity networks. Thus, combining CSF protein measures and rs-fcMRI in the present study provides a link between a-synuclein metabolism and disrupted brain function in PD.
However, DMN functional connectivity did not correlate with Ab measures in PD. Despite significantly lower CSF Ab 42 , the PD group surprisingly had stronger DMN functional connectivity than controls. Of note, DMN functional connectivity correlated with CSF Ab 42 levels only in the control group despite all control participants having normal cortical PiB binding and CSF Ab 42 (CSF Ab 42 .500 pg/mL). 13 These data suggest that the strength of DMN functional connectivity in our control participants correlates with the variability of CSF Ab 42 levels within the normal range but does not necessarily indicate that this reflects preclinical AD in these controls. People with preclinical AD may be more likely to have elevated Ab deposition several years before symptom onset, at least if the findings in familial AD can be extrapolated to sporadic AD 32 ; therefore, we excluded controls with abnormally elevated PiB binding. Thus, our findings indicate either that Ab 42 relates to DMN function in normal aging or that this relationship can develop many years before onset of sporadic AD. Nevertheless, our findings of stronger DMN functional connectivity in PD despite lower CSF Ab 42 levels directly contrast with findings in preclinical and symptomatic AD in which disruption of DMN correlates with reductions in CSF Ab 42 . These results reinforce the notion that Ab deposition has a different role in PD pathophysiology than in AD. Alternatively, the lack of an association between CSF Ab 42 and DMN functional connectivity in PD may reflect differences between the specific types of Ab plaques that occur in AD and PD. Neuritic plaques are a prominent pathologic feature of AD, whereas diffuse plaques are more common in PD. 36 Given that relatively few participants with PD had abnormally elevated PiB binding, it remains possible that Ab plaque deposition must exceed a threshold level to disrupt DMN functional connectivity.
Overall, these results raise an interesting question about the role of soluble a-synuclein as measured in CSF vs insoluble, fibrillar a-synuclein aggregates found in Lewy bodies. Animal models of synucleinopathy demonstrate that a-synuclein oligomers impair synaptic function and long-term potentiation. 37, 38 For example, mice overexpressing oligomeric forms of a-synuclein have greater synaptic and dendritic loss than a-synuclein wild-type mice that express monomers, oligomers, and fibrillar a-synuclein. 37 Similarly, AD animal models also demonstrated that Ab oligomers impair synaptic function. 39 Identification of the specific roles of the various forms of a-synuclein in PD requires more advanced biochemical and neuroimaging methods.
This study has several important strengths. We investigated the relationships between CSF pathogenic protein levels and disruption of RSNs and found that CSF a-synuclein, but not Ab 42 , correlate with the strength of some cortical RSNs in PD. None of our control participants had evidence of preclinical AD, as indicated by normal PiB scans and CSF Ab 42 levels. 13, 31 Equally important, we rigorously controlled for movement in the rs-fcMRI analyses as a behavioral confound and for motion-related artifacts. Finally, functional connectivity analyses extended beyond the more traditional seed-based approach and used a network-level analysis strategy to examine functional connectivity within the major RSNs.
The principal limitation of the present study is the small number of participants with PD who had elevated PiB binding, thus hindering the ability to adequately test for group differences in DMN functional connectivity based on abnormally elevated Ab burden. Treating CSF and PiB Ab as continuous measures, however, revealed no correlations between DMN functional connectivity and either CSF Ab 42 or PiB binding in the PD group. The current study also did not control for possible PD-related atrophy; however, all previous studies that measured atrophy failed to find an association between disrupted functional connectivity and atrophy in PD. 4, 8, 9, 40 Combining protein measures and rs-fcMRI affords a greater understanding of the pathologic basis for motor impairment in PD. This approach could also provide valuable insight into nonmotor features of PD. Determination of the utility of these measures to detect and predict PD progression requires longitudinal studies incorporating CSF measures and rs-fcMRI. 
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